Professor Mark Gumbleton
Mark is Professor in Experimental Therapeutics and Director of Research in the School Pharmaceutical Sciences, Cardiff University, UK. Current activity is at the interface of experimental therapeutics and biological barriers research, with the latter represented by the biology of the Blood Brain Barrier. Aligned to this he has cancer research interests in neuro-oncology and in cancer stem cell biology more widely, and in particular the role of the protein, caveolin-1. A current Cancer Research Wales funded project is addressing the function of caveolin-1 as a stem cell molecule in renal cell carcinoma.